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INTRODUCTION
Apo2L/TRAIL (Apo2 ligand or tumor necrosis factor
(TNF)-related apoptosis-inducing ligand) was discovered by
its sequence homology to TNF and CD95L (1, 2). Recom-
binant soluble human Apo2L/TRAIL is a candidate for clin-
ical investigation in cancer therapy because it induces apop-
tosis in a broad spectrum of human cancer cell lines but not
in many normal cells, and exhibits potent anti-tumor activ-
ity without normal tissue toxicity in various cancer xenograft
models (3-7). To date, four homologous, but distinct, human
TRAIL (hTRAIL) receptors have been identified, with two
(DR4/TR1 [8] and DR5/TR2 [9-11]) having the ability to
initiate the apoptosis signaling cascade after ligation, and
two (TRID/DcR1/TR3 [9, 11, 12] and TRUNDD/DcR2/
TR4 [13-15]) lacking this ability. Because they lack the ability
to directly signal cell death, TR3 and TR4 have been hypoth-
esized as being protective receptors, either by acting as decoy
receptors (8, 14, 15) or via transduction of an antiapoptotic
signal (13).
Glioblastoma multiforme (GBM) is the most malignant
and common brain tumor, comprising 23% of all primary
brain tumors in adults. GBM tumors are refractory to all cur-
rent therapeutic approaches, including surgery, radiotherapy,
and chemotherapy (16). Human glioma cells express TR2
and undergo apoptosis upon TRAIL ligation in vitro (17, 18).
Local injection of TRAIL exerted strong antitumor activity
on intracranial human malignant glioma xenografts in athymic
mice in the absence of neurotoxicity (6). In combination with
conventional DNA-damaging chemotherapy, TRAIL showed
synergistic cytotoxicity for human gliomas in vivo and in
vitro (19). Therefore, systemic or intracranial TRAIL treat-
ment may be a promising approach for human GBM tumors.
However, one potential drawback to these findings was that
large amounts of soluble TRAIL were required to inhibit
tumor formation. This may be due to the pharmacokinetic
profile of soluble TRAIL that indicated that after intravenous
injection the majority of the protein is cleared within 5 hr
(4). Increasing the in vivo t1/2 of soluble rTRAIL or devel-
oping an alternative means of delivery may increase the rel-
ative tumoricidal activity of TRAIL such that larger, more
established tumors could be eradicated as efficiently as smaller
tumors. The results presented in this work describe the pro-
duction of an adenoviral vector engineered to carry the gene
for hTRAIL. After infection, TRAIL protein was detected,
leading to the induction of apoptosis in human malignant
glioblastoma cells in vitro as well as significant antitumor
activity in vivo. These results demonstrate the potential ther-
Ki-Uk Kim, Su-Yeong Seo,
Ki-Young Heo*, Young-Hyun Yoo,
Hye-Jin Kim, Hyeong-Sik Lee,
Sun-Seob Choi, Tae-Ho Hwang,
Hye-Jeong Lee
Brain Tumor Research, Dong-A University College of
Medicine, Busan; Department of Pathology*, Pusan
National University College of Medicine, Busan, Korea
Address for correspondence
Hye-Jeong Lee, M.D.
Department of Pharmacology, Dong-A University 
College of Medicine, Dongdaesin-dong, Seo-gu,
Busan 602-714, Korea
Tel : +82.51-240-2859, Fax : +82.51-241-0778
E-mail : hjlee@dau.ac.kr
*This study was supported by grant from the Korean
Science and Engineering Foundation (KOSEF) (R05-
2001-000-00460-0).
1046
J Korean Med Sci 2005; 20: 1046-52
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Antitumor Activity of TRAIL Recombinant Adenovirus in Human 
Malignant Glioma Cells
Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) has been report-
ed to specifically kill malignant cells but to be relatively nontoxic to normal cells. One
of disadvantages to previous in vivo protocols was the need for large quantities of
TRAIL recombinant protein to suppress tumor growth. To evaluate the antitumor
activity and therapeutic value of the TRAIL gene, we constructed adenoviral vectors
expressing the human TRAIL gene (Ad.hTRAIL) and transferred them into malig-
nant glioma cells in vitro and tumors in vivo, as an alternative to recombinant soluble
TRAIL protein. The results show that TRAIL-sensitive glioma cells infected Ad.hTRAIL
undergo apoptosis through the production and expression of TRAIL protein. The
in vitro transfer elicited apoptosis, as demonstrated by the quantification of viable
or apoptotic cells and by the analysis of cleavage of poly (ADP-ribose) polymerase.
Furthermore, in vivo administration of Ad.hTRAIL at the site of tumor implantation
suppressed the outgrowth of human glioma xenografts in SCID mice. These results
further define Ad.hTRAIL as an anti-tumor therapeutic and demonstrate its poten-
tial use as an alternative approach to treatment for malignant glioma.
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apeutic utility of adenoviral-mediated delivery of TRAIL
gene.
MATERIALS AND METHODS
Production of adenovirus encoding the hTRAIL gene 
The cDNA for hTRAIL was obtained from Dr. Hideo
Yagita (Juntendo University, Tokyo, Japan) (20). To generate
E1-deleted recombinant adenoviral vector encoding hTRAIL
(Ad.hTRAIL), hTRAIL cDNA was introduced into the shut-
tle plasmid, pAvCvSv, under the transcriptional control of
the cytomegalovirus (CMV) immediate early enhancer/pro-
moter (21). The recombinant shuttle plasmid was co-trans-
fected with the E1-deleted adenovirus serotype 5 genome,
pJM17 (22), into transformed human embryonic kidney cells,
designated 293 cells (23). A E1-deleted recombinant aden-
ovirus, containing a reporter  -galactosidase ( -Gal) gene
with CMV promoter (Ad.lacZ) was used for concurrent con-
trol. Recombinant adenoviruses were amplified on 293 cells
and purified by two centrifugation steps on cesium chloride
gradients (24). Viruses were dialyzed against 10 mM Tris
HCl pH 8.0, 1 mM MgCl2, 10% glycerol and stored at -80
℃ until use. The number of viral particles was assessed by
measurement of the optical density at 260 nm.
Cell culture
The p53-wild-type human malignant glioma cell lines
U87MG and the p53-mutated U373MG were obtained
from the American Type Culture Collection. Each of these
cell lines was maintained in growth medium consisting of
RPMI1640 supplemented with 10% fetal celf serum (Life
Technologies, Calsbad, CA, U.S.A.), and the following anti-
microbial agents: 100 IU/mL penicillin and 100  g/mL strep-
tomycin. Cultures were maintained at 37℃ in a humidified
atmosphere with 5% CO2 in air and subcultured every 4 to
7 days with 0.25% trypsin in HBSS (Life Technologies). 
Adenoviral infection 
Cells were cultured and permitted to adhere for at least
12 hr before adding adenovirus. Before infection, cells were
washed with PBS, and then the vectors were added at the
indicated number of multiplicity of infection (MOI)/cell in
PBS. After 30 min, cells were washed with PBS and incu-
bated in complete medium for the remainder of the assay. 
Western blotting and ELISA
Cells were cultured and harvested on second and third day
after infection of Ad.hTRAIL and treated with lysis buffer
(0.5% sod. deoxycholate, 0.5% Triton X-100, 50 mM Tris,
pH 7.4, 150 mM NaCl, 62.5 mM sucrose, 5 mM EDTA, 1
mM PMSF). Protein concentrations of the lysates were deter-
mined by the colorimetric bicinchoninic acid analysis (Pierce,
Rockford, IL, U.S.A.). Equal amounts of protein were sepa-
rated by SDS-PAGE, transferred to nitrocellulose membrane
(Novex, San Diego, CA, U.S.A.). The membrane was incu-
bated with the anti-PARP (BD Biosciences, San Jose, CA,
U.S.A.), or anti-hTRAIL mAb (BD Biosciences). For detec-
tion of secreted TRAIL, the medium of the TRAIL-express-
ing cell cultures were measured by ELISA (BD Biosciences).
Nuclear morphology for apoptosis
Cells were cytocentrifuged, stained in 4  g/mL Hoechst
33342 for 30 min at 37℃ and fixed for 10 min in 4% para-
formaldehyde.
MTT assay after Ad.hTRAIL infection 
Cells were infected with 10, 30, 100, 300, and 1,000 MOI
of Ad.hTRAIL; 10% (volume/volume) of stock MTT solu-
tion (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) (Sigma, St. Louis, MO, U.S.A.) dissolved in medi-
um at a concentration of 5 mg/mL was added to the medium
directly, and cells were incubated for 30 min at 37℃, to allow
cell-mediated reduction of MTT, to assay cell viability. The
medium was aspirated and cells were washed with phosphate-
buffered saline. DMSO (0.5 mL, equal to the volume of medi-
um) was added to solublize the dye. Absorbance was mea-
sured at 570 nm.
Assessment of antitumor activity in a SCID mice 
In vivo assessment of the effect of Ad.hTRAIL on glioma
growth was performed using a SCID mice (6-8 weeks old;
Daehan Laboratory Animal Center, Korea) by subcutaneous
inoculation of 1×106 U87MG glioma cells into the dorsal
flank of each mouse. This dose of cells produces virtually
100% tumor take in the SCID mouse system in our labora-
tory. To examine the apoptotic action of Ad.hTRAIL, 10 days
after tumor implantation, animals were randomly chosen to
receive either vehicle or 1×1010 particles of Ad.hTRAIL per
mouse administered by intratumoral injection a volume of
100  L. After 3 days the mice were sacrificed and the tumor
region was excised. Histological analysis was followed. Fur-
thermore, to determine the suppression of tumor growth of
Ad.hTRAIL, animals were administered with Ad.hTRAIL
or Ad.lacZ. Tumor volumes were measured every other day
for 30 days.
Histological procedures and TUNEL assay
The excised tumor tissues were fixed in 10% neutral-bu-
ffered formalin and embedded in paraffin. Five  m thick sec-1048 K.-U. Kim, S.-Y. Seo, K.-Y. Heo, et al.
tions were stained with hematoxylin-eosin for histological
examination. Apoptosis induced in tumor tissues was mea-
sured using the TUNEL assay (Apoptosis Detection Kit,
Chemicon, Temecula, CA, U.S.A.). Tissue sections, 5  m
thick, were deparaffinized and rehydrated through a series
of graded alcohols. The sections were processed in 0.05 M
sodium citrate buffer (pH 6.0) and heated in a microwave
for 10 min for antigene retrieval. Samples were subjected to
the reaction with terminal deoxynucleotidyl transferase in
the presence of digoxigenin-conjugated nucleotide substrate
at 37℃ for 30 min. After the reaction was stopped, the slides
were incubated with anti-digoxigenin antibody that had been
conjugated with peroxidase. The peroxidase was visualized
with DAB (3,3′ -diaminobenzidine tetrahydrochloride). Sec-
tions were counterstained with Mayer’s hematoxylin and then
coverslipped.
RESULTS
Production of TRAIL-encoding adenovirus and TRAIL
gene expression
The cDNA encoding full-length hTRAIL was inserted
into the E1 region of a replication-deficient Ad5 construct
under the control of the CMV immediate early promoter.
The engineered TRAIL-expressing adenovirus was infected
into U87MG and U373MG cells, and the cellular proteins
were separated by SDS-PAGE to assay for TRAIL expression
by Western blotting. Amino acid sequence analysis of the
TRAIL cDNA predicts a weight of 32.5 kDa for TRAIL
monomers (1, 2). Treatment of cells with Ad.hTRAIL resulted
in a strong TRAIL-specific band according to particle num-
ber of infection and period for incubation (Fig. 1). To con-
firm the secretion of TRAIL in the medium of the TRAIL-
expressing U87MG cell cultures, ELISA showed that the
concentration of TRAIL is 235±28 pg/mL. 
TRAIL-induced apoptosis in human malignant glioma
cells 
To test whether treatment with the Ad.hTRAIL, which
is known to elicit apoptosis in a variety of transformed or
malignant cells (3, 4), would similarly elicit apoptosis in
cultured cancer cells, the cell-killing effect of the Ad.hTRAIL
was analyzed by quantifying apoptotic cells by measuring
cell viability via MTT assay (Fig. 2). The results show a sig-
nificant difference in cell killing between lines in response
to treatment with TRAIL-expressing vectors versus control
vectors. Although MTT assay of the tumor cells infected with
Ad.hTRAIL as presented in Fig. 2 indicates the amount of
cell death, it does not discriminate between apoptotic and
necrotic cell death. Previous reports have demonstrated that
TRAIL-induced cell death occurs through an apoptotic mech-
anism characterized by the activation of a cascade of intra-
cellular proteases and the cleavage of numerous intracellular
proteins (25-27). To confirm that the tumor cell death fol-
lowing Ad.hTRAIL infection was mediated through an apop-
totic mechanism, nuclear fragmentation and cellular protein
cleavage were examined. Morphological studies using Hoechst
nuclear staining revealed nuclear condensation in cells treat-
ed with Ad.hTRAIL (Fig. 3A). U87MG and U373MG cells
were incubated with Ad.hTRAIL for 30 min, cell lysates were
prepared at various times after infection, and the cellular pro-
teins were separated by SDS-PAGE for Western blot analy-
sis of PARP cleavage as substrate for caspase-3 (Fig. 3B).
These results demonstrated that treatment with the TRAIL
gene effectively elicited apoptosis in cultured malignant
glioma cells.
Tumor growth suppression by intratumoral delivery of the
TRAIL gene in vivo
To further test the antitumor effect of the TRAIL gene,
human malignant glioma xenografts were established in SCID
mice by inoculating U87MG cells subcutaneously into the
dorsal flanks of mice as described above in ‘‘Materials and
Methods.’’ Histochemical analysis by H&E 3 days after intra-
tumoral injection of Ad.hTRAIL into preexisting tumor
revealed extensive disappearance of tumor cells in center which
demonstrated that intralesional administration of the TRAIL
gene effectively killed tumor cells (Fig. 4B). Ad.lacZ-infect-
ed tissue showed well preserved and proliferated tumor cells
(Fig. 4A). Furthermore, TUNEL assay demonstrated that the
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Fig. 1. Production of adenovirus-encoding human TRAIL. (A)
Ad.hTRAIL-infected U87MG cells express TRAIL protein accord-
ing to MOI and period for incubation. Cell lysates from uninfect-
ed or Ad.hTRAIL-infected U87MG cells were prepared 24 hr after
infection with different MOI (upper panel) and different incuba-
tion period with 300 MOI (lower panel). (B) Ad.hTRAIL-infected
U87MG cells secret TRAIL into the media and secreted TRAIL
was quantified by ELISA.Antitumor Activity of Adenoviral-mediated TRAIL Gene in Glioma 1049
Ad.hTRAIL-infected cells showed positive stain for apoptotic
cells at periphery (Fig. 4D). while Ad.lacZ-treated cells were
not stained (Fig. 4C). To demonstrate whether Ad.hTRAIL
was able to suppress growth of preexisting tumor, we gave a
single intratumoral injection of Ad.hTRAIL or Ad.lacZ at
7 days after tumor implantation. Ad.hTRAIL significantly
suppressed tumor growth (p<0.01) (Fig. 5). The growth of
the tumors treated with Ad.hTRAIL was well suppressed
until day 30 on average.
DISCUSSION
Human malignant glioma cells are highly resistant to mul-
tiple pro-apoptotic stimuli, including irradiation and cytotoxic
drugs. Although loss of p53 function and alterations in cell
cycle control genes have been attributed a role in this radioche-
moresistant phenotype, the precise molecular pathways medi-
ating glioma cell resistance to radiotherapy or chemotherapy
have not been elucidated. Therefore, death ligand, TRAIL
is potentially valuable agent for the induction of glioma cell
death (17, 28). TRAIL has become an attractive molecule
for the treatment of cancers because it specifically kills tumor
cells (3, 4). Recently it is reported that TRAIL induced apop-
tosis through death receptor 5 (DR5) and was mediated by
caspase-8-initiated extrinsic and intrinsic mitochondrial path-
ways in sensitive glioma cell lines. Furthermore, TRAIL alone
or in combination with chemotherapeutic agents, induced
apoptosis in primary tumor cultures from patients with malig-
nant gliomas, reinforcing the potential of TRAIL as an effec-
tive therapeutic agent for malignant gliomas (33). The tumor-
specific activity of TRAIL was extended in vivo with the
observation that treatment of SCID and nude mice bearing
human tumors with soluble TRAIL significantly inhibited
tumor outgrowth without any observable toxic side effects
to the host (5-7). This inhibition of tumor outgrowth, though,
required high amounts of recombinant TRAIL given over
several days shortly after tumor implantation. Pharmacoki-
netic analysis revealed that soluble TRAIL given to mice
intravenously displayed an elimination t1/2 of just under 5 hr
(4). An alternative approach would be to administer TRAIL
locally, where it would exist at a greater concentration and
have a better chance of significantly inducing tumor cell death.
Such localized, intratumoral injections of soluble TRAIL
would, however, be limited in that only a relatively small
volume could be administered, suggesting that a potentially
Fig. 3. Ad.hTRAIL-infected glioma cells undergo apoptotic cell
death. (A) Nuclear fragmentation was examined by Hoechst nuclear
staining in U87MG and U373MG cells treated with Ad.hTRAIL or
Ad.lacZ. (B) Cleavage of PARP from 118 to 85 kDa occurs during
apoptotic cell death. Cell lysates were prepared of various times
after infection with 300 MOI and cellular proteins were determined
by Western blot analysis.
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Fig. 2. Death of glioma cells after Ad.hTRAIL infection results from increased production of TRAIL protein. (A) U87MG cells. (B) U373MG
cells. 96 well plates were seeded with 5×10
4 cells/well and allowed to adhere for at least 12 hr before infection with Ad.hTRAIL or Ad.lacZ
at the indicated number of MOI. Cell viability was determined after 24 hr by MTT. Results shown are the mean±SEM from at least three
independent experiments. *p<0.05, 
� p<0.01.
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Fig. 4. In vivo assessment of cell death by intratumoral delivery of Ad.hTRAIL. Ten days after tumor implantation, Ad.hTRAIL was admin-
istered by intratumoral injection. After 3 days, the tumor regions was excised and analyzed. (A & B) Tumor tissues were stained with H&E
(×100) and Ad.lacZ-infected tissue (A) show well preserved and proliferated tumor cells. Ad.hTRAIL-infected tissue (B) showes markedly
reduced tumor cells in the center and only small numbers of the cells are present at periphery. (C & D) TUNEL assay demonstrates that
Ad.hTRAIL-infected cells (D) show positive stain for apoptotic cells at periphery and that Ad.lacZ-infected cells (C) are not stained for
apoptotic cells (×100). (E & F) Immunohistochemistry using anti-TRAIL antibody shows that Ad.hTRAIL expressed TRAIL protein in vivo
in Ad.hTRAIL-infected tumor cells (F). Ad.lacZ-infected tumor cells (E) are not detected by anti-TRAIL antibody.
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suboptimal amount of TRAIL protein would be used. In
contrast, Ad.hTRAIL can be produced at high titers, such
that small volumes would contain high numbers of infec-
tious adenoviral particles carrying the hTRAIL gene.
In the study reported here, we asked whether introducing
the TRAIL gene via adenoviral vector directly into malignant
glioma cells would result in the expression of biologically
active molecules that could effectively kill malignant cells
in vitro and in vivo. The data presented in this study describe
the generation of an adenoviral vector engineered to carry
the gene for hTRAIL. Ad.hTRAIL infection resulted in the
transcription and translation of the transferred hTRAIL gene
into functional TRAIL protein that, when expressed on the
cell surface, induced apoptotic death in malignant glioma
cells. One report described that adenoviral TRAIL gene trans-
fer is ineffective treatment strategy for malignant glioma
(29). In this study, however, adenoviral TRAIL gene transfer
showed apoptosis in human glioma cells and even induced
cell death in TRAIL-resistant glioma cells (U373MG). We
have found that treatment with TRAIL-expressing vectors
produced a substantial amount of TRAIL on the surface of
the cells and secreted soluble TRAIL in the medium of the
TRAIL-expressing cell cultures. These results suggest that
the apoptotic activity of TRAIL produced by adenoviral vec-
tor is elicited via both of membrane-bound TRAIL and solu-
ble TRAIL. The effects of soluble TRAIL may be dose-depen-
dent, conformation-dependent, or both. It has been report-
ed that trimerized recombinant TRAIL is more effective than
the monomer form; thus, conformational differences in sol-
uble TRAIL proteins may also dramatically affect their activ-
ities (30). Our data suggest that transmembrane expression
is indeed a highly potent strategy for expressing TRAIL. Why
transmembrane expression of TRAIL is so highly efficient
for inducing target cell apoptosis is unclear, although possi-
bilities include transmembrane TRAIL undergoing oligomer-
ization at the cell membrane following binding to its recep-
tor on target cells. 
The present study examined the possible therapeutic value
of an adenovirus encoding TRAIL gene for the treatment of
malignant glioma. This virus has previously been shown to
kill melanoma, breast carcinoma cell lines (27), prostate and
bladder carcinoma cells (31), and lung, colon cancer cell lines
(32). In this study, we demonstrated that Ad.hTRAIL induces
cell death of malignant glioma. Our data confirm recent stud-
ies demonstrating antitumor activity of Ad.hTRAIL, and
suggest TRAIL gene transfer as a potential alternative strat-
egy for the efficient delivery of TRAIL.
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